Nifty 17401.65 (1.37%)
Sensex 58461.29 (1.35%)
Nifty Bank 36508.25 (0.39%)
Nifty IT 36157.85 (2.06%)
Nifty Financial Services 17982.9 (1.26%)
Adani Ports 739.10 (4.40%)
Asian Paints 3180.60 (1.35%)
Axis Bank 676.10 (-0.52%)
B P C L 378.85 (2.74%)
Bajaj Auto 3328.40 (2.43%)
Bajaj Finance 7180.50 (2.01%)
Bajaj Finserv 17758.15 (2.16%)
Bharti Airtel 732.55 (1.43%)
Britannia Inds. 3578.50 (1.22%)
Cipla 921.25 (-0.74%)
Coal India 159.30 (2.41%)
Divis Lab. 4777.30 (0.53%)
Dr Reddys Labs 4662.75 (1.22%)
Eicher Motors 2451.55 (0.54%)
Grasim Inds 1723.85 (2.63%)
H D F C 2807.80 (3.85%)
HCL Technologies 1184.70 (2.42%)
HDFC Bank 1525.75 (1.40%)
HDFC Life Insur. 705.30 (1.65%)
Hero Motocorp 2472.70 (1.00%)
Hind. Unilever 2383.30 (1.64%)
Hindalco Inds. 432.10 (1.69%)
I O C L 120.65 (2.51%)
ICICI Bank 722.40 (-0.73%)
IndusInd Bank 945.55 (1.27%)
Infosys 1748.25 (1.94%)
ITC 225.45 (1.60%)
JSW Steel 646.75 (1.50%)
Kotak Mah. Bank 1964.25 (0.56%)
Larsen & Toubro 1789.20 (0.18%)
M & M 849.55 (1.78%)
Maruti Suzuki 7324.95 (0.71%)
Nestle India 19503.20 (0.54%)
NTPC 128.70 (0.78%)
O N G C 144.00 (1.23%)
Power Grid Corpn 214.50 (3.52%)
Reliance Industr 2482.85 (0.64%)
SBI Life Insuran 1188.05 (1.99%)
Shree Cement 26289.80 (0.76%)
St Bk of India 477.00 (0.36%)
Sun Pharma.Inds. 766.25 (2.80%)
Tata Consumer 773.25 (0.06%)
Tata Motors 479.10 (0.81%)
Tata Steel 1112.40 (2.76%)
TCS 3642.90 (1.82%)
Tech Mahindra 1629.65 (2.65%)
Titan Company 2386.50 (1.11%)
UltraTech Cem. 7323.20 (0.01%)
UPL 698.20 (1.12%)
Wipro 646.80 (1.89%)
INFY

Caplin Point Laboratories..

₹802.5
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

As per analysts rating in the last 6 months, the recommendation is to HOLD Caplin Point Lab

  • Master Rating:
  • Caplin Point Labs. has an operating revenue of Rs. 1,157.07 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 30% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 12% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 26% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 93 which is a GREAT score indicating consistency in earnings, a RS Rating of 61 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 149 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Caplin Point Laboratories Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Caplin Point Laboratories Ltd Synopsis

NSE-Medical-Generic Drugs

Caplin Point Lab is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 482.68 Cr. and Equity Capital is Rs. 15.13 Cr. for the Year ended 31/03/2021. Caplin Point Laboratories Ltd. is a Public Limited Listed company incorporated on 16/04/1990 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24231TN1990PLC019053 and registration number is 019053.
  • Market Cap

    INR 6,080.46 Cr

  • Sales

    INR 533.94 Cr

  • Shares in Float

    2.35 Cr

  • No of Funds

    52 K

  • Yield

    0.37%

  • Book Value

    8

  • U/D Vol Ratio

    1.4

  • LTDebt/Equity

    %

  • Alpha

    0.14

  • Beta

    0.78

Caplin Point Laboratories Ltd Ownership
Caplin Point Laboratories Ltd Management

Caplin Point Laboratories Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 758.6734599.9054432.045295.6043200.1161
Fixed Assets Annual Cr 184.048170.6982146.3861184.6102155.1658
Total Non Current Assets Annual Cr 328.3547310.591251.374197.5929180.337
Total Current Assets Annual Cr 532.6478380.7363287.9513213.2094136.7281
Total Assets Annual Cr 861.0025691.3273539.3253410.8023317.0651
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 100.296479.307457.125639.099226.4786
ROE Annual % 20.5932.9434.2934.6135.13
ROCE Annual % 26.8140.3944.3745.1742.13
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 48.1751.7141.6338.731.02

Caplin Point Laboratories Ltd Technicals

EMA & SMA

CURRENT PRICE

802.5 (4.87)

    • Bullish Moving Averages 9
    • Bearish Moving Averages 7

EMA

  • 20 Day

    807.39

  • 50 Day

    827.86

  • 100 Day

    795.88

  • 200 Day

    683.47

Caplin Point Laboratories Ltd Resistance and support

757.74 PIVOT

  • First Resistance

    787.47

  • Second Resistance

    809.74

  • Third Resistance

    839.47

  • First Support

    735.47

  • Second Support

    705.74

  • Third Support

    683.47

  • RSI

    46.44

  • MFI

    60.98

  • MACD

    -24.91

  • MACD signal line

    -20.43

Caplin Point Laboratories Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 569,501 7,967,319 13.99%
Week 369,081 11,972,975 32.44%
1 Month 203,455 7,275,560 35.76%
6 Month 572,246 13,499,281 23.59%

Caplin Point Laboratories Ltd Price change analysis

-26.55

Over 1 month

Low High
722.25 890

64

Over 3 month

Low High
722.25 1008.4

212.15

Over 6 months

Low High
585 1034.8

321.05

Over Year

Low High
401 1034.8

Similar Stocks

News

CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 3

Loss of Share Certificate of Mr. Ganesan R Read More

Buy Caplin Point Laboratories; target of Rs 1080: ICICI Dire

ICICI Direct is bullish on Caplin Point Laboratories has recommended buy rating on the stock with a target price of Rs 1080 in its research Read More

Caplin Labs Standalone September 2021 Net Sales at Rs 160.40

NULL Read More

Caplin Point Laboratories Ltd - 524742 - Announcement under

Allotment of Equity Shares on Exercise of ESOPs Read More

Earnings Call for Q2FY22 of Caplin Point Laboratories

Conference Call with Caplin Point Laboratories Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transc Read More

Blogs

FAQs